Glancy Binkow & Goldberg Announces Lead Plaintiff Deadline In The Class
Action Lawsuit Against Edwards Lifesciences Corporation
LOS ANGELES -- September 23, 2013
Glancy Binkow & Goldberg LLP, representing investors of Edwards Lifesciences
Corporation (“Edwards Lifesciences” or the “Company”) (NYSE:EW), announces
that purchasers of the Company’s common stock between April 25, 2012 and April
23, 2013, inclusive (the “Class Period’), have until November 18, 2013 to file
a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in
the United States District Court for the Central District of California.
A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW &
GOLDBERG LLP. PLEASE CONTACT US AT (212) 682-5340, TOLL-FREE AT (888)
773-9224, OR AT SHAREHOLDERS@GLANCYLAW.COM TO DISCUSS THIS MATTER. IF YOU
INQUIRE BY EMAIL PLEASE INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND
NUMBER OF SHARES PURCHASED.
Edwards Lifesciences’ is a medical device maker that designs and markets,
among other things, artificial heart valves for implantation in patients with
advanced cardiovascular disease. The Company offers a range of such valves,
including both valves that require traditional open-chest surgery, and its
newer SAPIEN line of transcatheter heart valves (“THVs”), which may be
implanted using a minimally invasive procedure.
The Complaint alleges that the Company issued false and/or misleading
statements and failed to disclose material facts related to the prospects,
projected sales and adoption of the Company’s Edwards SAPIEN transcatheter
aortic heart valve, including the related transfemoral and transapical
delivery methods (“SAPIEN”), and related projections of financial performance
for the Company’s operations. Specifically, the Complaint alleges that the
defendants knew but concealed from Edwards Lifesciences’ shareholders during
the Class Period that: (1) adoption of SAPIEN was weaker than the Company
claimed, due to concerns among physicians over the risks and complexity of the
procedure for implanting the valve; (2)Edwards Lifesciences’ outlook for
sales and earnings per share (“EPS”) was significantly weaker than the
optimistic guidance defendants offered to investors; and (3)as a result,
defendants lacked a reasonable basis for the statements made concerning the
Company’s operations, forecasts and outlook.
On April 23, 2013, the Company disclosed that approximately 20 candidate
hospitals had postponed SAPIEN training, that there was substantially no
backlog of patients awaiting SAPIEN implants, and that the Company’s financial
results had been and would likely continue to be weaker than estimates. In
response to this news, Edwards Lifesciences’ stock price fell $18.21 per
share, or 21.99 percent, to close at $64.60 per share on April 24, 2013 on
extremely heavy trading volume.
If you are a member of the Class described above you may move the Court no
later than November 18, 2013 to serve as lead plaintiff; however, you must
meet certain legal requirements. To be a member of the Class you need not take
any action at this time; you may retain counsel of your choice or take no
action and remain an absent member of the Class.
To learn more about this action, or if you have any questions concerning this
Notice or your rights or interests with respect to these matters, please
contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925
Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at
(888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg
LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212)
682-5340, by e-mail to firstname.lastname@example.org, or visit our website at
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Glancy Binkow & Goldberg LLP, Los Angeles, CA
Glancy Binkow & Goldberg LLP, New York, NY
Press spacebar to pause and continue. Press esc to stop.